Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ALK F1174L HRAS Q61L |
Therapy | Lorlatinib |
Indication/Tumor Type | neuroblastoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK F1174L HRAS Q61L | neuroblastoma | predicted - resistant | Lorlatinib | Case Reports/Case Series | Actionable | In a clinical case study, HRAS Q61L was identified in a post-progression biopsy in a pediatric patient with metastatic neuroblastoma harboring ALK F1174L, who previously achieved a partial response on Lorbrena (lorlatinib) treatment (PMID: 39177282). | 39177282 |
PubMed Id | Reference Title | Details |
---|---|---|
(39177282) | Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis. | Full reference... |